pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
165
stories
8d
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
stat
9d
Nordic biotech’s next act: From fragmentation to global force
biospace
9d
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
9d
STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
stat
9d
Crystalys nets $130M more to push gout drug through late-stage tests
biopharma dive
10d
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
endpoints
10d
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
10d
Agios scraps sickle cell drug
biopharma dive
10d
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
biopharma dive
10d
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
biospace
10d
Crystalys mines $130M series B to push gout drug through phase 3
fiercebiotech
10d
Is there an exodus underway at Epic?
stat
10d
STAT+: Anthropic deepens work with rare disease drugs
stat
10d
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
stat
10d
STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environment
stat
11d
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
stat
11d
Agios says adios to sickle cell program over lackluster phase 2 data
fiercebiotech
11d
Recon: Novo sues Lilly over weight-loss drug ads; Gilead, Merck say HIV pill keeps HIV suppressed in two Phase 3 trials
raps
11d
Pain drugmaker Latigo outlines plans to go public
biopharma dive
11d
STAT+: Pharmalittle: We’re reading about a telehealth firm and patient safety, PBMs overcharging, and more
stat
11d
HHS vaccine committee quietly gets new charter
stat
12d
STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer
stat
12d
STAT+: Telemedicine company touted by Novo Nordisk stressed profits over patient safety, ex-workers say
stat
12d
Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
biospace
14d
Compounders maintain a firm grip on the GLP-1 market
biopharma dive
15d
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
16d
STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
stat
17d
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
biopharma dive
17d
STAT+: Akero team, backed by Fairmount, launches new immunology company
stat
21d
STAT+: Roche ends Huntington’s gene-silencing programs
stat
← prev
page 2 of 6
next →
